| Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds E Proschak, H Stark, D Merk Journal of medicinal chemistry 62 (2), 420-444, 2018 | 454 | 2018 |
| PocketPicker: analysis of ligand binding-sites with shape descriptors M Weisel, E Proschak, G Schneider Chemistry Central Journal 1, 1-17, 2007 | 428 | 2007 |
| Spirocyclic scaffolds in medicinal chemistry K Hiesinger, D Dar’in, E Proschak, M Krasavin Journal of Medicinal Chemistry 64 (1), 150-183, 2020 | 415 | 2020 |
| DOGS: Reaction-Driven de novo Design of Bioactive Compounds M Hartenfeller, H Zettl, M Walter, M Rupp, F Reisen, E Proschak, ... PLoS computational biology 8 (2), e1002380, 2012 | 270 | 2012 |
| The holistic integration of virtual screening in drug discovery Y Tanrikulu, B Krüger, E Proschak Drug Discovery Today 18 (7-8), 358-364, 2013 | 208 | 2013 |
| Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria FM Klingler, TA Wichelhaus, D Frank, J Cuesta-Bernal, J El-Delik, ... Journal of medicinal chemistry 58 (8), 3626-3630, 2015 | 186 | 2015 |
| Inhibitors of the arachidonic acid cascade: interfering with multiple pathways K Meirer, D Steinhilber, E Proschak Basic & clinical pharmacology & toxicology 114 (1), 83-91, 2014 | 176 | 2014 |
| Multi-target approaches in metabolic syndrome FF Lillich, JD Imig, E Proschak Frontiers in pharmacology 11, 554961, 2021 | 105 | 2021 |
| Multitarget‐Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases ÓM Bautista‐Aguilera, S Hagenow, A Palomino‐Antolin, V Farré‐Alins, ... Angewandte Chemie International Edition 56 (41), 12765-12769, 2017 | 101 | 2017 |
| Voyages to the (un) known: adaptive design of bioactive compounds G Schneider, M Hartenfeller, M Reutlinger, Y Tanrikulu, E Proschak, ... Trends in biotechnology 27 (1), 18-26, 2009 | 101 | 2009 |
| Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization M Hartenfeller, E Proschak, A Schüller, G Schneider Chemical biology & drug design 72 (1), 16-26, 2008 | 100 | 2008 |
| Computational tools for polypharmacology and repurposing J Achenbach, P Tiikkainen, L Franke, E Proschak Future medicinal chemistry 3 (8), 961-968, 2011 | 96 | 2011 |
| Opportunities and challenges for fatty acid mimetics in drug discovery E Proschak, P Heitel, L Kalinowsky, D Merk Journal of medicinal chemistry 60 (13), 5235-5266, 2017 | 94 | 2017 |
| Lipoxin and resolvin biosynthesis is dependent on 5‐lipoxygenase activating protein C Lehmann, J Homann, AK Ball, R Blöcher, TK Kleinschmidt, ... The FASEB Journal 29 (12), 5029-5043, 2015 | 93 | 2015 |
| Kernel approach to molecular similarity based on iterative graph similarity M Rupp, E Proschak, G Schneider Journal of chemical information and modeling 47 (6), 2280-2286, 2007 | 89 | 2007 |
| A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis J Schmidt, M Rotter, T Weiser, S Wittmann, L Weizel, A Kaiser, J Heering, ... Journal of medicinal chemistry 60 (18), 7703-7724, 2017 | 86 | 2017 |
| 2, 4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization K Sander, T Kottke, Y Tanrikulu, E Proschak, L Weizel, EH Schneider, ... Bioorganic & medicinal chemistry 17 (20), 7186-7196, 2009 | 83 | 2009 |
| Nonacidic farnesoid X receptor modulators D Flesch, SY Cheung, J Schmidt, M Gabler, P Heitel, J Kramer, A Kaiser, ... Journal of Medicinal Chemistry 60 (16), 7199-7205, 2017 | 82 | 2017 |
| PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation S Kolodziej, ON Kuvardina, T Oellerich, J Herglotz, I Backert, N Kohrs, ... Nature communications 5 (1), 3995, 2014 | 70 | 2014 |
| SAR-study on a new class of imidazo [1, 2-a] pyridine-based inhibitors of 5-lipoxygenase M Hieke, CB Rödl, JM Wisniewska, E la Buscató, H Stark, ... Bioorganic & medicinal chemistry letters 22 (5), 1969-1975, 2012 | 70 | 2012 |
Holger StarkHeinrich Heine University Duesseldorf/GermanyEmail verificata su hhu.de